|
RU2347813C2
|
|
Neisseria antigens
|
|
US2004087020A1
|
|
Culture medium with yeast or soy bean extract as amino acid source and no protein complexes of animal origin
|
|
GB0230163D0
|
|
Modified saccharides having improved stability in water
|
|
GB0229494D0
|
|
Modified saccharides having improved stability in water
|
|
GB0227346D0
|
|
741
|
|
GB0226734D0
|
|
Unexpected meningococcus surface proteins
|
|
GB0223741D0
|
|
Composition with five meningococcal antigens
|
|
GB0223355D0
|
|
Vaccine
|
|
GB0220194D0
|
|
Improved vesicles
|
|
GB0220195D0
|
|
Modified saccharides having improved stability in water
|
|
GB0220198D0
|
|
Modified saccharides,conjugates thereof and their manufacture
|
|
GB0220205D0
|
|
Neisseria toxin
|
|
GB0218924D0
|
|
Immunisation against chlamydia trachtomatis
|
|
GB0218233D0
|
|
Immunisation against chlamydia trachomatis
|
|
CN1535158A
|
|
Vaccines comprising aluminium adjuvants and histidine
|
|
GB0211025D0
|
|
Meningococcus adhesins
|
|
GB0210128D0
|
|
Nucleic acids and proteins from streptococcus groups A & B
|
|
GB0207117D0
|
|
Modified saccharides having improved stability in water
|
|
GB0205018D0
|
|
Heliobacter pylori vaccination
|
|
GB0203403D0
|
|
Chlamydia cytotoxic-T cell epitopes
|
